- Home
- DXYZ vs IVA Comparison
DXYZ vs IVA Comparison
Compare DXYZ & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXYZ
- IVA
- Stock Information
- Founded
- DXYZ N/A
- IVA 2011
- Country
- DXYZ
- IVA France
- Employees
- DXYZ N/A
- IVA N/A
- Industry
- DXYZ
- IVA Biotechnology: Pharmaceutical Preparations
- Sector
- DXYZ
- IVA Health Care
- Exchange
- DXYZ Nasdaq
- IVA Nasdaq
- Market Cap
- DXYZ 313.1M
- IVA 359.6M
- IPO Year
- DXYZ 2024
- IVA 2020
- Fundamental
- Price
- DXYZ $25.82
- IVA $5.57
- Analyst Decision
- DXYZ
- IVA Strong Buy
- Analyst Count
- DXYZ 0
- IVA 6
- Target Price
- DXYZ N/A
- IVA $15.33
- AVG Volume (30 Days)
- DXYZ N/A
- IVA 71.1K
- Earning Date
- DXYZ N/A
- IVA 09-26-2025
- Dividend Yield
- DXYZ N/A
- IVA N/A
- EPS Growth
- DXYZ N/A
- IVA N/A
- EPS
- DXYZ N/A
- IVA N/A
- Revenue
- DXYZ N/A
- IVA $14,591,573.00
- Revenue This Year
- DXYZ N/A
- IVA $80.35
- Revenue Next Year
- DXYZ N/A
- IVA N/A
- P/E Ratio
- DXYZ N/A
- IVA N/A
- Revenue Growth
- DXYZ N/A
- IVA N/A
- 52 Week Low
- DXYZ N/A
- IVA $1.53
- 52 Week High
- DXYZ N/A
- IVA $6.50
- Technical
- Relative Strength Index (RSI)
- DXYZ 31.43
- IVA 62.61
- Support Level
- DXYZ $26.32
- IVA $5.21
- Resistance Level
- DXYZ $27.55
- IVA $6.10
- Average True Range (ATR)
- DXYZ 1.27
- IVA 0.41
- MACD
- DXYZ 0.04
- IVA 0.07
- Stochastic Oscillator
- DXYZ 6.04
- IVA 61.04
About DXYZ Destiny Tech100 Inc. Common Stock
Destiny Tech100 Inc is a non-diversified, closed-end management investment company. It invests in a portfolio of what is believed to be 100 of the top venture-backed private technology companies.
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.